Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Olaf Sommerburg - , Heidelberg University , Translational Lung Research Center Heidelberg (TLRC) - DZL Heidelberg (Author)
  • Veronika Krulisova - , Charles University Prague (Author)
  • Jutta Hammermann - , Department of Paediatrics, University Hospital Carl Gustav Carus Dresden (Author)
  • Martin Lindner - , Heidelberg University  (Author)
  • Mirjam Stahl - , Heidelberg University , Translational Lung Research Center Heidelberg (TLRC) - DZL Heidelberg (Author)
  • Martina Muckenthaler - , Heidelberg University , Translational Lung Research Center Heidelberg (TLRC) - DZL Heidelberg (Author)
  • Dirk Kohlmueller - , Heidelberg University  (Author)
  • Margit Happich - , Heidelberg University  (Author)
  • Andreas E. Kulozik - , Heidelberg University  (Author)
  • Felix Votava - , Charles University Prague (Author)
  • Miroslava Balascakova - , Charles University Prague (Author)
  • Veronika Skalicka - , Charles University Prague (Author)
  • Marina Stopsack - , University Hospital Carl Gustav Carus Dresden, Institute for Clinical Chemistry and Laboratory Medicine (Author)
  • Manfred Gahr - , University Hospital Carl Gustav Carus Dresden, Institute for Clinical Chemistry and Laboratory Medicine (Author)
  • Milan Macek - , Charles University Prague (Author)
  • Marcus A. Mall - , Heidelberg University , Translational Lung Research Center Heidelberg (TLRC) - DZL Heidelberg (Author)
  • Georg F. Hoffmann - , Heidelberg University , Translational Lung Research Center Heidelberg (TLRC) - DZL Heidelberg (Author)

Abstract

Background: In recent years different IRT/PAP protocols have been evaluated, but the individual performance remains unclear. To optimize the IRT/PAP strategy we compared protocols from three regional CF newborn screening centers (Heidelberg, Dresden, and Prague). Methods: We evaluated the effect of elevating the IRT-cut-off from 50 to 65. μg/l (~. 97.5th to ~. 99.0th percentile), the need of a failsafe protocol (FS, IRT. ≥. 99.9th percentile) and the relative performance using either two IRT-dependent PAP-cut-offs or one PAP-cut-off. Findings: Elevation of the IRT cut-off to 65. μg/l (~. 99.0th percentile) increased the PPV significantly (Dresden: 0.065 vs. 0.080, p. <. 0.0001, Prague: 0.052 vs. 0.074, p. <. 0.0001) without reducing sensitivity. All three IRT/PAP protocols showed a trend towards a higher sensitivity with FS than without and when using one PAP-cut-off instead of two IRT-dependent PAP-cut-offs. Conclusions: For best performance we suggest an IRT/PAP protocol with an IRT-cut-off close to the 99.0th percentile, FS, and a single PAP-cut-off.

Details

Original languageEnglish
Pages (from-to)15-23
Number of pages9
JournalJournal of cystic fibrosis
Volume13
Issue number1
Publication statusPublished - Jan 2014
Peer-reviewedYes

External IDs

PubMed 23891278

Keywords

Keywords

  • Biochemical screening, Cystic fibrosis, Immunoreactive trypsinogen, Newborn screening, Pancreatitis associated protein